3 Enzyme, Hydration and Diagnostic Health Stocks With a Strong Future Roadmap: Advanced Enzyme Technologies, FDC and Suraksha Diagnostic
- October 12, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Advanced Enzyme Rs 267.15, P/E 17.28. FDC Rs 330.15, P/E 18.05. Suraksha Diagnostic Rs 316.25, P/E 46.05. Closing prices of 9 Oct 2026.
Quick Answer
Enzyme, hydration and diagnostic health stocks with the clearest long-term roadmaps today include Advanced Enzyme in enzymes and probiotics for food and pharma, FDC in oral rehydration products such as Electral and formulations and Suraksha Diagnostic in diagnostic and pathology testing. FY26 revenue growth was 16.5% at Advanced Enzyme, 3.9% at FDC and 22.5% at Suraksha Diagnostic. P/E stands at 17.28 for Advanced Enzyme (industry 37.59), 18.05 for FDC (industry 37.59) and 46.05 for Suraksha Diagnostic (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Enzyme, hydration and diagnostic health stocks give investors exposure to ingredients, health products and lab tests used in everyday healthcare. Volumes, product mix and margins decide how much of that demand turns into profit.
This list covers three enzyme, hydration and diagnostic health stocks: Advanced Enzyme Technologies for enzymes and probiotics for food and pharma, FDC for oral rehydration products such as Electral and formulations and Suraksha Diagnostic for diagnostic and pathology testing. Every figure comes from the latest reported financials and the 9 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Enzyme, Hydration and Diagnostic Health Stocks?
Enzyme, hydration and diagnostic health stocks are shares of companies that make health ingredients and brands or run diagnostic labs. Results depend on volumes, product mix and margins, so product mix and margins separate the stronger names.
Enzyme, Hydration and Diagnostic Health Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three enzyme, hydration and diagnostic health stocks as of the 9 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Advanced Enzyme Technologies | 267.15 | 2,967 | 17.28 | 37.59 | 10.34% | 0.02 |
| FDC | 330.15 | 5,281 | 18.05 | 37.59 | 11.32% | 0.01 |
| Suraksha Diagnostic | 316.25 | 1,614 | 46.05 | 62.79 | 13.15% | 0.53 |
Among healthcare stocks, all three trade at a discount to their industry P/E multiples.
Why Do Enzyme, Hydration and Diagnostic Health Stocks Have a Strong Roadmap in India?
Enzyme, hydration and diagnostic health stocks have a strong roadmap in India because health spending keeps rising with more tests, nutrition products and trusted brands, which supports ingredient makers, brands and labs. Three drivers stand out.
- Health awareness: More families use preventive tests and nutrition products.
- Trusted brands: Familiar names win repeat purchases.
- Ingredient demand: Food and pharma firms need enzymes and probiotics.
Advanced Enzyme Technologies: Enzymes and Probiotics Build the Next Leg
Advanced Enzyme’s roadmap rests on enzymes and probiotics for food, nutrition, pharma and animal feed, with a wide industrial customer base supporting revenue.
Revenue grew from Rs 535.80 crore in FY22 to Rs 780.59 crore in FY26, a 45.7% rise, and FY26 revenue was 16.5% higher than FY25. FY26 net profit rose 29.6% to Rs 173.61 crore. Over four years, net profit rose from Rs 123.80 crore in FY22 to Rs 173.61 crore. In Q1 FY27, revenue grew 4.1% to Rs 202.81 crore. Operating margin was 37.06% in FY26.
Debt to equity is 0.02 and return on equity is 10.34%. FY26 operating cash flow was Rs 156.78 crore against capital expenditure of Rs 52.38 crore. Advanced Enzyme paid a dividend of Rs 5.35 per share for FY26, a yield of 2.02%. At a P/E of 17.28 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: The P/E of 17.28 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
FDC: Established Brands Drive the Pipeline
FDC’s roadmap rests on oral rehydration products such as Electral along with eye, ear and anti-infective formulations, with established brands supporting steady sales.
Revenue grew from Rs 1,604.01 crore in FY22 to Rs 2,284.45 crore in FY26, a 42.4% rise, and FY26 revenue was 3.9% higher than FY25. FY26 net profit rose 5.5% to Rs 281.42 crore. Over four years, net profit rose from Rs 216.16 crore in FY22 to Rs 281.42 crore. In Q1 FY27, revenue grew 4.6% to Rs 715.35 crore, and net profit rose 9.2% to Rs 132.49 crore. Operating margin was 20.21% in FY26 and 28.56% in Q1 FY27 against 27.12% a year earlier.
Debt to equity is 0.01 and return on equity is 11.32%. FY26 operating cash flow was Rs 200.45 crore against capital expenditure of Rs 186.56 crore. FDC paid a dividend of Rs 5 per share for FY26, a yield of 1.54%. At a P/E of 18.05 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 28.56% against 20.21% for FY26, so margin stability is the figure to follow as volumes grow.
Suraksha Diagnostic: Diagnostic Labs Drive the Pipeline
Suraksha Diagnostic’s roadmap rests on diagnostic and pathology testing through a network of labs and collection centres, with rising health screening supporting test volumes.
Revenue grew from Rs 225.50 crore in FY22 to Rs 313.58 crore in FY26, a 39.1% rise, and FY26 revenue was 22.5% higher than FY25. FY26 net profit rose 1.4% to Rs 31.40 crore. Over four years, net profit rose from Rs 23.75 crore in FY22 to Rs 31.40 crore. In Q1 FY27, revenue grew 20.7% to Rs 88.74 crore, and net profit rose 40.0% to Rs 12.85 crore. Operating margin was 32.01% in FY26 and 35.97% in Q1 FY27 against 33.97% a year earlier.
Debt to equity is 0.53 and return on equity is 13.15%. FY26 operating cash flow was Rs 81.83 crore against capital expenditure of Rs 67.34 crore. Suraksha Diagnostic paid a dividend of Rs 0.05 per share for FY26, a yield of 0.02%. At a P/E of 46.05 against an industry P/E of 62.79, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 35.97% against 32.01% for FY26, so margin stability is the figure to follow as volumes grow.
Best Enzyme, Hydration and Diagnostic Health Stocks in India: Advanced Enzyme vs FDC vs Suraksha Diagnostic on Key Financials
Among the best enzyme, hydration and diagnostic health stocks in India, Advanced Enzyme leads on FY26 operating margin and FY26 net profit growth; FDC leads on the lowest debt to equity; Suraksha Diagnostic leads on FY26 revenue growth and Q1 FY27 revenue growth. The table puts the numbers side by side.
| Metric | Advanced Enzyme | FDC | Suraksha Diagnostic |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 780.59 | 2,284.45 | 313.58 |
| FY26 revenue growth | 16.5% | 3.9% | 22.5% |
| FY26 net profit (Rs Cr) | 173.61 | 281.42 | 31.40 |
| FY26 net profit growth | 29.6% | 5.5% | 1.4% |
| FY26 operating profit margin | 37.06% | 20.21% | 32.01% |
| Q1 FY27 revenue growth (YoY) | 4.1% | 4.6% | 20.7% |
| Return on equity | 10.34% | 11.32% | 13.15% |
| P/E ratio | 17.28 | 18.05 | 46.05 |
| Debt to equity | 0.02 | 0.01 | 0.53 |
| Dividend yield | 2.02% | 1.54% | 0.02% |
| FY26 operating cash flow (Rs Cr) | 156.78 | 200.45 | 81.83 |
Healthcare earnings follow volumes, product mix and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Enzyme, Hydration and Diagnostic Health Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen enzyme, hydration and diagnostic health stocks and shortlist enzyme, hydration and diagnostic health stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check margins, growth and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these enzyme, hydration and diagnostic health stocks
Risks to Consider Before Investing in Enzyme, Hydration and Diagnostic Health Stocks
- Pricing pressure: Competition can affect margins.
- Regulation: Rule changes can affect products and lab operations.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Advanced Enzyme, FDC and Suraksha Diagnostic live.
Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare stocks cover enzymes, rehydration products and diagnostic testing. Advanced Enzyme leads on FY26 operating margin and FY26 net profit growth; FDC leads on the lowest debt to equity; Suraksha Diagnostic leads on FY26 revenue growth and Q1 FY27 revenue growth.
Across enzyme, hydration and diagnostic health stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the enzyme, hydration and diagnostic health stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Enzyme, Hydration and Diagnostic Health Stocks
Which are the best enzyme, hydration and diagnostic health stocks in India with a strong roadmap?
Ans. Advanced Enzyme Technologies, FDC and Suraksha Diagnostic stand out for their roadmaps in enzymes, rehydration products and diagnostic testing. FY26 revenue growth was 16.5% at Advanced Enzyme, 3.9% at FDC and 22.5% at Suraksha Diagnostic, and return on equity ranges from 10.34% to 13.15%.
Is Advanced Enzyme Technologies a good stock to buy now?
Ans. Advanced Enzyme Technologies has a debt to equity ratio of 0.02, a return on equity of 10.34% and a P/E of 17.28 against an industry P/E of 37.59. Valuation, pricing and regulation move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Advanced Enzyme, FDC and Suraksha Diagnostic?
Ans. The P/E ratio is 17.28 for Advanced Enzyme (industry 37.59), 18.05 for FDC (industry 37.59) and 46.05 for Suraksha Diagnostic (industry 62.79). All of them trade below the industry multiple.
Which of these enzyme, hydration and diagnostic health stocks has the highest return on equity?
Ans. Suraksha Diagnostic has the highest return on equity at 13.15%, followed by FDC at 11.32% and Advanced Enzyme Technologies at 10.34%.
What are the risks of investing in enzyme, hydration and diagnostic health stocks?
Ans. The main risks are pricing pressure, regulation and quarterly trends. Competition can affect margins.
How did Advanced Enzyme, FDC and Suraksha Diagnostic perform in Q1 FY27?
Ans. Advanced Enzyme Technologies reported revenue of Rs 202.81 crore, up 4.1% year on year. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore. Suraksha Diagnostic reported revenue of Rs 88.74 crore, up 20.7% year on year, and net profit rose 40.0% to Rs 12.85 crore.
Do enzyme, hydration and diagnostic health stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 2.02% for Advanced Enzyme, 1.54% for FDC and 0.02% for Suraksha Diagnostic, based on dividends declared for FY26.
How can I invest in enzyme, hydration and diagnostic health stocks in India?
Ans. You can buy enzyme, hydration and diagnostic health stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
